Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease

Journal of Immunology

Volumn 183, Issue 5, 2009, Pages 3454-3462

  Di Sabatino, Antonio ^a,c   Rovedatti, Laura ^a,c   Kaur, Rejbinder ^b   Spencer, Jonathan P ^b   Brown, Jon T ^b   Morisset, Valerie D ^b   Biancheri, Paolo ^a,c   Leakey, Nicholas A B ^a   Wilde, Jonathan I ^b   Scott, Laurie ^b   Corazza, Gino R ^c   Lee, Kevin ^b   Sengupta, Neel ^a   Knowles, Charles H ^a   Gunthorpe, Martin J ^b   McLean, Peter G ^b   MacDonald, Thomas T ^a   Kruidenier, Laurens ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 FLUORO PYRIDINE 4 CARBOXYLIC ACID (2',5' DIMETHOXY BIPHENYL 4 YL) AMIDE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL; GAMMA INTERFERON; GSK 1349571A; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 8; RADIOLIGAND; T BOX TRANSCRIPTION FACTOR; TACROLIMUS; THAPSIGARGIN; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; CALCIUM CHANNEL; CYTOKINE; T BOX TRANSCRIPTION FACTOR TBX21; T-BOX TRANSCRIPTION FACTOR TBX21;

ADULT; AGED; ANIMAL CELL; ARTICLE; BINDING COMPETITION; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUOROMETRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; INTESTINE BIOPSY; INTESTINE CELL; LAMINA PROPRIA; LEUKEMIA CELL LINE; MAST CELL LEUKEMIA; MONONUCLEAR CELL; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; T LYMPHOCYTE; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CELL LINE, TUMOR; CYTOKINES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; JURKAT CELLS; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PATCH-CLAMP TECHNIQUES; RATS; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 70349232511     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802887     Document Type: Article

References (53)

1. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533. (Pubitemid 37328672)
2. Fantini, M. C., G. Monteleone, and T. T. MacDonald. 2007. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1419-1423.
3. Elson, C. O., Y. Cong, S. Brandwein, C. T. Weaver, R. P. McCabe, M. Mähler, J. P. Sundberg, and E. H. Leiter. 1998. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann. NY Acad. Sci. 859: 85-95.
4. MacDonald, T. T., and G. Monteleone. 2005. Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925.
5. Neurath, M. F., B. Weigmann, S. Finotto, J. Glickman, E. Nieuwenhuis, H. Iijima, A. Mizoguchi, E. Mizoguchi, J. Mudter, P. R. Galle, et al. 2002. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195: 1129-1143.
6. Matsuoka, K., N. Inoue, T. Sato, S. Okamoto, T. Hisamatsu, Y. Kishi, A. Sakuraba, O. Hitotsumatsu, H. Ogata, K. Koganei, et al. 2004. T-bet upregulation and subsequent interleukin 12 stimulation are essential for induction of Th1 mediated immunopathology in Crohn's disease. Gut 53: 1303-1308.
7. Monteleone, G., L. Biancone, R. Marasco, G. Morrone, O. Marasco, F. Luzza, and F. Pallone. 1997. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112: 1169-1178.
8. Gordon, J. N., A. Di Sabatino, and T. T. MacDonald. 2005. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21: 431-437. (Pubitemid 40961169)
9. Liu, J. 1993. FK506 and cyclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol. Sci. 14: 182-188. (Pubitemid 23168862)
10. Hommes, D. W., T. L. Mikhajlova, S. Stoinov, D. Stimac, B. Vucelic, J. Lonovics, M. Zákuciová, G. D'Haens, G. Van Assche, S. Ba, et al. 2006. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55: 1131-1137.
11. Van Assche, G., W. J. Sandborn, B. G. Feagan, B. A. Salzberg, D. Silvers, P. S. Monroe, W. M. Pandak, F. H. Anderson, J. F. Valentine, G. E. Wild, et al. 2006. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55: 1568-1574.
12. Creed, T. J., C. S. Probert, M. N. Norman, M. Moorghen, N. A. Shepherd, S. D. Hearing, and C. M. Dayan. 2006. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment. Pharmacol. Ther. 23: 1435-1442.
13. Plevy, S., B. Salzberg, G. Van Assche, M. Regueiro, D. Hommes, W. Sandborn, S. Hanauer, S. Targan, L. Mayer, U. Mahadevan, et al. 2007. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133: 1414-1422.
14. Stronkhorst, A., S. Radema, S. L. Yong, H. Bijl, I. J. ten Berge, G. N. Tytgat, and S. J. van Deventer. 1997. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 40: 320-327.
15. 2+ signaling in T cells. Trends Mol. Med. 13: 103-107.
16. Lewis, R. S. 2001. Calcium signaling mechanisms in T lymphocytes. Annu. Rev. Immunol. 19: 497-521.
17. Parekh, A. B., and J. W. Putney. 2005. Store-operated calcium channels. Physiol. Rev. 85: 757-810.
18. Macian, F. 2005. NFAT proteins: key regulators of T-cell development and function. Nat. Rev. Immunol. 5: 472-484.
19. + channel gating in T cells from immunodeficient patients. J. Exp. Med. 202: 651-662.
20. Feske, S. 2007. Calcium signalling in lymphocyte activation and disease. Nat. Rev. Immunol. 7: 690-702. (Pubitemid 47327393)
21. 2+ influx and IL-2 production in T lymphocytes. J. Immunol. 170: 4441-4449.
22. 2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2. J. Biol. Chem. 279: 12427-12437.
23. Best, W. R., J. M. Becktel, J. W. Singleton, and F. Kern. 1976. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 70: 439-444.
24. Rachmilewitz, D. 1989. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized study. Br. Med. J. 298: 82-86.
25. Di Sabatino, A., K. M. Pickard, J. N. Gordon, V. Salvati, G. Mazzarella, M. R. Beattie, A. Vossenkaemper, L. Rovedatti, N. A. B. Leakey, N. M. Croft, et al. 2007. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 133: 1175-1187.
26. 2+] using the Fluorometric Imaging Plate Reader (FLIPR). Methods Mol. Biol. 114: 125-133.
27. Di Sabatino, A., S. L. F. Pender, C. L. Jackson, J. D. Prothero, J. N. Gordon, L. Picariello, L. Rovedatti, G. Docena, G. Monteleone, D. S. Rampton, et al. 2007. Functional modulation of Crohn's disease myofibroblasts by anti-TNF antibodies. Gastroenterology 133: 137-149.
28. Hoth, M., and R. Penner. 1992. Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 355: 353-356.
29. Hoth, M., and R. Penner. 1993. Calcium release-activated calcium current in rat mast cells. J. Physiol. 465: 359-386. (Pubitemid 23201401)
30. Gwack, Y., S. Srikanth, S. Feske, F. Cruz-Guilloty, M. Oh-hora, D. S. Neems, P. G. Hogan, and A. Rao. 2007. Biochemical and functional characterization of Orai proteins. J. Biol. Chem. 282: 16232-16243.
31. 2+ channels. J. Biol. Chem. 283: 31348-31355.
32. Weigmann, B., H. A. Lehr, G. Yancopoulos, D. Valenzuela, A. Murphy, S. Stevens, J. Schmidt, P. R. Galle, S. Rose-John, and M. F. Neurath. 2008. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J. Exp. Med. 205: 2099-2110.
33. 2+ signaling in identified T-lymphocytes from human intestinal mucosa: relation to hyporeactivity, proliferation, and inflammatory bowel disease. J. Biol. Chem. 279: 5641-5647.
34. Tutsch, E., D. Griesemer, A. Schwarz, A. Stallmach, and M. Hoth. 2004. Two-photon analysis of calcium signals in T lymphocytes of intact lamina propria from human intestine. Eur. J. Immunol. 34: 3477-3484.
35. 2+ response amplitude and duration. Nature 386: 855-858.
36. Neurath, M. F., S. Pettersson, K. H. Meyer zum Büschenfelde, and W. Strober. 1996. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat. Med. 2: 998-1004.
37. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2: 725-734.
38. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70.
39. Kolls, J. K., and A. Linden. 2004. Interleukin-17 family members and inflammation. Immunity 21: 467-476.
40. Baggiolini, M., P. Loetscher, and B. Moser. 1995. Interleukin-8 and the chemokine family. Int. J. Immunopharmacol. 17: 103-108.
41. Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman, and L. H. Glimcher. 2000. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100: 655-669.
42. Weigmann, B., and M. F. Neurath. 2002. T-bet and mucosal Th1 responses in the gastrointestinal tract. Gut 51: 301-303.
43. Monteleone, I., G. Monteleone, G. Del Vecchio Blanco, P. Vavassori, S. Cucchiara, T. T. MacDonald, and F. Pallone. 2004. Regulation of the T helper cell type 1 transcription factor T-bet in coeliac disease mucosa. Gut 53: 1090-1095.
44. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 280: 243-248.
45. Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279: 1737-1740.
46. Boirivant, M., M. Marini, G. Di Felice, A. M. Pronio, C. Montesani, R. Tersigni, and W. Strober. 1999. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565. (Pubitemid 29106763)
47. Di Sabatino, A., R. Ciccocioppo, B. Cinque, D. Millimaggi, R. Morera, L. Ricevuti, M. G. Cifone, and G. R. Corazza. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase-dependent pathway in Crohn's disease. Gut 53: 70-77.
48. Shen, C., G. V. Assche, S. Colpaert, P. Maerten, K. Geboes, P. Rutgeerts, and J. L. Ceuppens. 2005. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21: 251-258.
49. Lügering, A., P. Lebiedz, S. Koch, and T. Kucharzik. 2006. Apoptosis as a therapeutic tool in IBD? Ann. NY Acad. Sci. 1072: 62-77.
50. D. C. Baumgart, and W. J. Sandborn. 2007. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657.
51. Gomes, B., M. D. Cabral, A. Gallard, M. Savignac, P. Paulet, P. Druet, B. Mariamé, M. Moreau, C. Leclerc, J.-C. Guéry, and L. Pelletier. 2007. Calcium channel blocker prevents T helper type 2 cell-mediated airway inflammation. Am. J. Respir. Crit. Care Med. 175: 1117-1124.
52. Feske, S., Y. Gwack, M. Prakriya, S. Srikanth, S. H. Puppel, B. Tanasa, P.G. Hogan, R.S. Lewis, M. Daly, and A. Rao. 2006. A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. Nature 441: 179-185.
53. Lewis, R. S. 2007. The molecular choreography of a store-operated calcium channel. Nature 446: 284-287.